Clinical Problem Summary

• Elderly female (inferred)
• Presenting complaint: Reeling sensation (dizziness/vertigo)
• Chronic non-healing ulcer, right ankle, lateral malleolus, 9 months
• Bicytopenia: Hb 6.5 g/dL (↓ PCV, normal MCV, normal MCHC → normocytic normochromic anemia) + Platelets 90,000/µL
• WBC 5,400 (normal)
• Prior LCA (Left Coronary Artery) territory stent — 3 years ago
• Medications: Aspirin + Clopidogrel + Atorvastatin + Pentoxifylline + Cilostazol

Step 1: Deconstructing the "Reeling Sensation"

Differential Diagnosis — Ranked by Likelihood

Step 2: Medication Review — Critical Issues

A. Cilostazol Overlap with Clopidogrel

• Aspirin (COX-1 inhibitor)
• Clopidogrel (P2Y12 inhibitor)
• Cilostazol (PDE3 inhibitor with antiplatelet + vasodilatory effects)

Per Harrison's (p. 7770): Cilostazol increases claudication distance by 40–60% but its mechanism is incompletely understood. Pentoxifylline modestly increases exercise duration with unconfirmed efficacy in larger trials.

• Consider stopping cilostazol — it is contributing to dizziness and is likely redundant alongside clopidogrel + aspirin for a patient already on DAPT
• Pentoxifylline may be continued for its rheologic benefits on the ulcer, but monitor BP

B. DAPT Duration

• At 3 years post-stent, continuing dual antiplatelet therapy indefinitely is not guideline-supported unless there is a compelling indication (high ischemic risk)
• However, if the stent was for ACS (STEMI/NSTEMI), prolonged DAPT may be justified — but must be weighed against bleeding risk (thrombocytopenia, Hb 6.5)
• Consult cardiology regarding whether to continue DAPT vs. transition to aspirin monotherapy

Step 3: Bicytopenia Workup

Priority Differential Diagnoses

Recommended Workup

1. Peripheral blood smear — morphology (blast cells, schistocytes, hypersegmented neutrophils, dysplastic changes)
2. Reticulocyte count — to differentiate hypoproliferative vs. hemolytic
3. Serum B12, folate, iron studies, ferritin, TIBC
4. LDH, indirect bilirubin, direct Coombs test — rule out hemolysis
5. Liver function tests, renal function
6. ANA, anti-dsDNA if autoimmune suspected
7. Bone marrow biopsy — if peripheral smear and labs suggest MDS or marrow pathology
8. Flow cytometry if lymphoproliferative disease suspected

Step 4: Management of the Reeling Sensation — Prioritized Approach

Immediate

1. Correct the anemia:
   • Hb 6.5 g/dL warrants packed red cell transfusion in a symptomatic patient with cardiovascular disease (post-coronary stent — transfusion threshold ≥8 g/dL in cardiac patients per guidelines)
   • Target Hb ≥9–10 g/dL given prior coronary disease
   • Pre-transfusion: check blood group, crossmatch, direct Coombs
2. Review and rationalize medications:
   • Stop cilostazol (primary contributor to dizziness; redundant with DAPT; thrombocytopenia is a relative contraindication)
   • Reassess DAPT need with cardiology — 3 years post-stent, stable patient
   • Continue pentoxifylline (beneficial for the ulcer)
   • Continue atorvastatin (secondary prevention, beneficial for vasculopathic ulcer)
3. Assess for BPPV:
   • Perform Dix-Hallpike maneuver
   • If positive → Epley maneuver (canalith repositioning) — highly effective, safe, non-pharmacological
   • If BPPV confirmed, no vestibular suppressants needed
4. Check orthostatic blood pressure (lying/sitting/standing) — if orthostatic hypotension present:
   • Encourage adequate hydration
   • Slow positional changes
   • Reassess vasodilatory medications
5. Cardiovascular/neurological assessment:
   • ECG — rule out arrhythmia (atrial fibrillation can cause embolic vertigo)
   • If vertebrobasilar TIA suspected: MRI brain + MRA posterior circulation
   • Carotid Doppler if clinically indicated

Step 5: Management of the Chronic Ulcer

• Lateral malleolus location strongly suggests arterial (ischemic) ulcer rather than venous (venous ulcers are typically medial malleolus/gaiter area)
• ABI (Ankle-Brachial Index) must be performed to assess arterial supply
  • ABI <0.9 → peripheral arterial disease
  • ABI <0.5 or ankle pressure <50 mmHg → critical limb ischemia
• If arterial: vascular surgery referral for revascularization assessment
• Biopsy is mandatory at 9 months to exclude Marjolin's ulcer (squamous cell carcinoma in a chronic ulcer) per Bailey & Love's (p. 55)
• Wound care: moist wound dressings, debridement of necrotic tissue
• Compression bandaging is CONTRAINDICATED if ABI <0.6
• If mixed arterio-venous: modified compression only after vascular assessment

Summary Action Plan

Non-Healing Ulcer — Right Lateral Malleolus, 9 Months

Step 1: Establish the Ulcer Type First

• Lateral malleolus location
• Systemic atherosclerosis (coronary stent in LCA territory)
• Already on medications for peripheral vascular disease (pentoxifylline, cilostazol)

Step 2: Mandatory Initial Assessment

A. Ankle-Brachial Index (ABI)

Per Global Vascular Guidelines (GVG 2019): Toe pressure is the preferred hemodynamic measure in suspected CLTI. Objective hemodynamic testing is mandatory.

B. Additional Investigations

• Duplex arterial ultrasound — maps occlusion/stenosis level
• CT Angiography or MR Angiography — pre-revascularization planning
• Wound swab/culture — assess for infection (critical colonization vs. overt infection)
• Ulcer biopsy — mandatory at 9 months to exclude Marjolin's ulcer (squamous cell carcinoma in a chronic wound) — Bailey & Love's (p. 55)
• Blood glucose, HbA1c — exclude undiagnosed/uncontrolled diabetes

Step 3: Wound Bed Preparation — TIME Framework

T — Tissue Debridement

• Remove necrotic, sloughy, or non-viable tissue to expose healthy wound bed
• Methods:
  • Sharp/surgical debridement — most effective, fastest; do cautiously if ABI <0.5
  • Autolytic debridement — hydrogel/hydrocolloid dressings (gentle, suitable for ischemic ulcers)
  • Enzymatic debridement — collagenase preparations
  • Maggot (larval) therapy — effective for heavily sloughed wounds, excellent evidence
  • Ultrasonic/NPWT-assisted debridement

I — Infection / Inflammation Control

• Clinical signs: increased pain, erythema, warmth, purulent exudate, malodor, wound breakdown
• Superficial/critical colonization: Topical antimicrobials (silver-containing dressings, iodine-based e.g., cadexomer iodine, PHMB dressings)
• Deep/spreading infection: Systemic antibiotics guided by wound culture
• Biofilm disruption: Mandatory in chronic non-healing wounds — use mechanical cleansing + antimicrobial dressings (biofilm is the primary reason ulcers do not heal)

M — Moisture Balance

• Wound must be moist but not macerated
• Exudate management by dressing type:

E — Edge Advancement / Epithelial Progression

• If edges are rolled, undermined, or non-advancing → re-debride
• Consider advanced wound therapies if no progress after 4–6 weeks of optimal wound care:
  • Negative Pressure Wound Therapy (NPWT/VAC) — promotes granulation, reduces edema, draws edges together
  • Skin grafting (split-thickness) — once wound bed is clean and granulating
  • Bioengineered skin substitutes (e.g., Apligraf, Dermagraft)
  • Growth factor therapy (becaplermin/PDGF) — limited evidence outside diabetic foot

Step 4: Revascularization — The Most Critical Intervention

Per GVG 2019 (p. 1): CLTI is defined as PAD + ulceration >2 weeks duration. All patients with suspected CLTI should be referred urgently to a vascular specialist. No wound will heal in ischemic tissue without restoring perfusion.

Revascularization Options

Step 5: Compression — With Caution

• Compression is beneficial for venous ulcers — improves healing and prevents recurrence (Grade 1B)
• Mixed arteriovenous ulcer: Compression only if ABI >0.5 or ankle pressure >60 mmHg (Grade 2C)
• Arterial ulcer with ABI <0.5: Compression is contraindicated — will worsen ischemia

Step 6: Systemic / Adjunctive Medical Management

Step 7: Surgical Options for Non-Healing Wounds

1. Split-thickness skin grafting (STSG) — after wound bed optimization
2. Flap reconstruction — if periosteum/tendon exposed (lateral malleolus area)
3. Amputation — last resort for non-salvageable limbs with gangrene, uncontrolled infection, or unrevascularizable disease

Management Algorithm Summary

Lateral malleolus ulcer (9 months)
            ↓
     Measure ABI + Toe pressure
            ↓
  ABI <0.5 → Urgent vascular surgery referral
  ABI 0.5–0.9 → Wound care + vascular referral
  ABI >0.9 → Exclude other causes
            ↓
   Wound bed preparation (TIME)
   + Biopsy (mandatory at 9 months)
   + Infection control
            ↓
   Revascularization (endovascular/bypass)
            ↓
   Correct anemia (transfuse to Hb ≥9)
   Optimize nutrition
   Best medical therapy
            ↓
   If wound bed clean + granulating
            ↓
      Skin grafting / NPWT / Advanced therapies

Imaging Modality Selection for This Patient

Patient-Specific Factors That Influence Choice

Head-to-Head Comparison

1. Lower Limb Arterial + Venous Duplex Doppler Ultrasound

2. CT Angiography (CTA) of Lower Limbs

3. MR Angiography (MRA) of Lower Limbs

4. Digital Subtraction Angiography (DSA) — The Gold Standard

• Gold standard, especially for below-knee and pedal vessels (IWGDF 2023, GVG 2019)
• Used when MRA/CTA fail to define anatomy adequately, or when endovascular intervention is planned simultaneously
• Invasive, requires arterial puncture → bleeding risk relevant here given DAPT + thrombocytopenia
• In most centres, DSA is reserved for the intervention suite

Patient-Specific Recommendation

Recommended Sequence for This Patient:

Step 1 (Always first):
Lower limb ARTERIAL + VENOUS DUPLEX DOPPLER
→ Establishes ABI, toe pressures, venous reflux
→ No contrast, no radiation, safe with any renal function
→ Determines if revascularisation is needed

           ↓ If revascularisation is being planned:

Step 2A: Check eGFR / serum creatinine
           ↓
  eGFR >45 → CT Angiography
  (excellent for aortoiliac-femoral anatomy,
   calcification mapping, pre-op planning)

  eGFR <45 OR heavy tibial calcification on CTA
  OR CTA inconclusive
           ↓
  MR Angiography (non-contrast if eGFR <30)
  Check coronary stent MRI compatibility first

           ↓ If anatomy still unclear OR intervention planned:

Step 3: DSA (diagnostic + therapeutic in same sitting)

Summary Table